Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer

Table 1

The main characteristics of included studies in meta-analysis.

Reference	Country	Ethnicity	Patient spectrum	Source of control	Sample size		miRNA profiling	Specimen	TP	FP	FN	TN	QUADAS-2
					Cases	Controls
[3]	Japan	Asian	PDAC	DC	32	42	miR-483-3p, miR-21	Plasma	31	2	1	40	8
[41]	USA	Caucasian	PaC	CP + HC	28	21	A set of 9 miRNAs	Tissue	28	4	0	17	8
[42]	USA	Caucasian	PaC	DC	80	57	miR-21	Tissue	63	13	17	44	6
[55]	USA	Caucasian	PaC	HC	64	54	miR-155, miR-21	Tissue	52	1	12	53	8
[11]	USA	Caucasian	PDAC	HC	39	29	miR-21, miR-210, miR-155, miR-196a	Plasma	18	2	10	23	7
[43]	France	Caucasian	PDAC	CP	39	20	miR-148a	Tissue	18	2	21	18	8
[21]	China	Asian	PaC	HC	36	30	miR-18a	Plasma	34	7	2	29	9
[44]	USA	Caucasian	PaC	HC	24	16	miR-21, miR-221, miR-17-3p	Pancreatic juice	19	4	5	12	10
[45]	South America; Spain; Middle East	Caucasian	PDAC	DC	157	29	A set of 7 miRNAs	Tissue	148	5	9	24	8
[13]	China	Asian	PaC	CP + HC	62	97	miR-155	Plasma	39	15	23	82	7
[12]	China	Asian	PDAC	CP + HC	45	75	miR-21	Plasma	32	23	13	52	6
[22]	China	Asian	PaC	CP	29	22	miR-181b, miR-196b, miR-210	Fecal	20	13	9	9	7
[46]	Germany	Caucasian	PDAC	CP	45	38	A set of 100 miRNAs	Blood	35	18	10	20	7
[24]	China	Asian	PaC	CP + HC	138	175	miR-16, miR-196a	Plasma	89	37	49	138	8
[23]	China	Asian	PaC	CP + HC	95	81	A set of 7 miRNAs	Serum	90	6	5	75	8
[47]	Germany	Caucasian	PDAC	CP	42	33	miR-135b	Tissue	39	2	3	31	6
[48]	USA	Caucasian	PDAC	DC	26	11	miR-21, miR-221, miR-155, miR-100, miR-196a, miR-181b	Tissue	24	3	2	8	9
[25]	China	Asian	PaC	HC	29	13	miR-181b, miR-210, miR-196a	Fecal	25	6	4	7	7
[49]	Denmark	Caucasian	PDAC	HC	160	28	A set of 9 miRNAs	Tissue	158	8	2	20	6
[26]	China	Asian	PaC	HC	24	24	miR-451, miR-409-3p	Plasma	22	2	2	22	6
[50]	USA	Caucasian	PDAC	CP	41	35	miR-1290, miR-146a	Serum	34	11	7	24	7
[27]	China	Asian	PaC	DC	129	163	miR-27a-3p	Blood	106	34	23	129	7
[28]	China	Asian	PDAC	HC	70	40	miR-192	Serum	53	18	17	22	5
[29]	China	Asian	PaC	DC	22	27	miR-21, miR-17-5p	Serum	21	5	1	22	8
[51]	Germany	Caucasian	PaC	DC	75	53	miR-1246, miR-4644, miR-3976, miR-4306	Serum	61	5	14	48	7
[14]	USA	Caucasian	PaC	HC	11	11	miR-885-5p, miR-22-3p, miR-642b-3p	Blood	10	1	1	10	5
[52]	USA	Caucasian	PDAC	DC	40	54	A set of 5 miRNAs	Plasma	38	0	2	54	8
[30]	China	Asian	PaC	HC	49	27	miR-492, miR-663a	Serum	42	5	7	22	6
[53]	Denmark	Caucasian	PaC	HC	180	199	A set of 10 miRNAs	Blood	153	29	27	170	8
[35]	China	Asian	PDAC	HC	30	15	miR-21, miR-155, miR-216	Fecal	28	5	2	10	8
[32]	China	Asian	PDAC	HC	70	40	miR-192, miR-194	Serum	59	10	11	30	7
[33]	China	Asian	PaC	HC	30	26	miR-210, miR-25	Plasma	22	7	8	19	6
[34]	China	Asian	PaC	CP + HC	60	30	miR-155, miR-196a	Plasma	46	9	14	21	6
[31]	China	Asian	PDAC	HC	30	15	miR-21, miR-155, miR-216	Fecal	25	2	5	13	6
[36]	Japan	Asian	PaC	HC	71	67	Circulating miR-223	Plasma	44	4	27	63	7
[54]	USA	Caucasian	PaC	HC	42	24	A set of 30 miRNAs	Plasma	34	11	8	13	7
[37]	China	Asian	PaC	CP + HC	60	30	miR-155, miR-21, miR-196a, miR-210	Plasma	57	2	3	28	6
[38]	China	Asian	PaC	HC	43	21	miR-21, miR-155	Plasma	38	3	5	18	5
[39]	China	Asian	PDAC	CP	110	70	miR-155	Serum	83	14	27	56	8
[40]	China	Asian	PaC	DC	16	20	miR-21, miR-29a, miR-210	Serum	13	9	3	11	6

PaC: pancreatic cancer; PDAC: pancreatic ductal adenocarcinoma; HC: healthy control; CP: chronic pancreatitis; DC: disease control; TP: true positive; FP: false positive; FN: false negative; TN: true negative.